Modeling Stress-precipitated Smoking Behavior for Medication Development
Conditions
Smoking
Trial Phase
Phase 2
Trial Purpose and Description
Trial Purpose
The purpose of this study is to examine whether guanfacine or carvedilol will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers. Participants seeking treatment for smoking will participate in a smoking cessation attempt after the laboratory sessions. Also looking at gender differences.
Participation Guidelines
- Age:
- 18 Years - 60 Years
- Gender:
- Both
Eligibility Criteria
Inclusion Criteria:
- ages 18-60
- able to read and write in English
- smokers
Exclusion Criteria:
- any significant current medical conditions that would contraindicate smoking
- current DSM-IV abuse or dependence of other substances, other than nicotine (or
caffeine) dependence
- positive test result at intake appointments on urine drug screens conducted for
opiates, cocaine, or benzodiazepines
- women who are pregnant or nursing
- suicidal, homicidal or evidence of severe mental illness
- participants prescribed any psychotropic drug in the 30 days prior to study
enrollment
- blood donation within the past 6 weeks
- participants who have engaged in a quit attempt in the past 3 months
- specific exclusions for administration of guanfacine/carvedilol not already specified
include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG; EKG
evidence at baseline screening of any clinically significant conduction
abnormalities, including a Bazlett's QTc >450 msec for men and QTc>470 msec for
women; known intolerance for guanfacine
- Sponsor:
- National Institute on Drug Abuse (NIDA)
- Office of Research on Women's Health (ORWH)
- Yale University
- Dates:
- October 2008
- Last Updated:
- July 31, 2012
- Study HIC#:
- 0808004163
Clinicaltrials.gov ID: NCT00773357
